Nicholas M. Pajewski

Jul 16, 2024 | agsjournals.onlinelibrary.wiley.com | Nicholas M. Pajewski

For conditions that often entail significant impairment, such as Alzheimer's disease or stroke, there is an established standard in clinical trials to adopt outcome measures that integrate function in both cognitive and physical domains, such as the Clinical Dementia Rating Scale1 and the modified Rankin Scale.2 What is perhaps a newer direction is adopting a similar paradigm, blending the brain and the body, within the context of prevention.

Jul 1, 2024 | agsjournals.onlinelibrary.wiley.com | Mark A. Espeland |Michael P. Bancks |Nicholas M. Pajewski |Johnathan Ross

Corresponding Author Mark A. Espeland PhD Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA Department of Biostatistics and Data Science, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA Correspondence Mark A. Espeland, Department of Internal Medicine, Section on Gerontology and Geriatric Medicine, Wake Forest University School of Medicine, One Medical Center Blvd, Winston-Salem, NC 27101, USA.

Feb 8, 2024 | thelancet.com | Nicholas M. Pajewski |Jordana B. Cohen

Hypertension is a leading risk factor for dementia, cardiovascular disease, and death in older adults. Although intensive blood pressure control effectively reduces cardiovascular morbidity and mortality, older and frail adults might be more susceptible to adverse effects such as hypotension, falls, and electrolyte abnormalities.